Evidence map›Paper›PMID 34242859›Full record

ArticleJournal of chromatography. B, Analytical technologies in the biomedical and life sciences2021

A positive-negative switching LC-MS/MS method for quantification of fenoldopam and its phase II metabolites: Applications to a pharmacokinetic study in rats.

Ting Du, Rongjin Sun, Nyma Siddiqui, Linda Moatamed, Yun Zhang, Dong Liang, Ming Hu, Song Gao

Open access · greenAbstract read
In one paragraph

Article in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ting DuDepartment of Pharmaceutical Science, College of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.
Rongjin SunDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, The University of Houston, 4901 Calhoun Street, Houston, TX 77204, USA.
Nyma SiddiquiDepartment of Pharmaceutical Science, College of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.
Linda MoatamedDepartment of Pharmaceutical Science, College of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.
Yun ZhangDepartment of Pharmaceutical Science, College of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.
Dong LiangDepartment of Pharmaceutical Science, College of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA.
Ming HuDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, The University of Houston, 4901 Calhoun Street, Houston, TX 77204, USA.
Song GaoDepartment of Pharmaceutical Science, College of Pharmacy and Health Sciences, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA. Electronic address: song.gao@tsu.edu.
Texas Southern University · USUniversity of Houston · US

Funding

Targeted Nano-drug-delivery-systems of Frist-in-class Drugs for CRPC: PK/PD Evaluation and Combination TherapyU54MD007605 · NIMHD · TEXAS SOUTHERN UNIVERSITY · PI Song Gao · 2020 to 2026
$22.0M
Center for Biomedical and Health Research Excellence (CBHRE)G12MD007605 · NIMHD · TEXAS SOUTHERN UNIVERSITY · PI OYEKAN, ADEBAYO O., WILSON, BOBBY L · 2014 to 2018
$7.1M
Developing Locally Bioavailable Drugs to Inhibit the Aberrantly Elevated PEG2 in the ColonR15GM126475 · NIGMS · TEXAS SOUTHERN UNIVERSITY · PI GAO, SONG · 2018 to 2018
$472k
NIGMS NIH HHS R15 GM126475NIMHD NIH HHS G12 MD007605NIMHD NIH HHS U54 MD007605
6 · The paper itself

Abstract

Fenoldopam is an approved drug used to treat hypotension. The purpose of this study is to develop and validate an LC-MS method to quantify fenoldopam and its major metabolites fenoldopam-glucuronide and fenoldopam-sulfate in plasma and apply the method to a pharmacokinetic study in rats. A Waters C

Indexed as

FenoldopamAnimalsChromatography, LiquidFemaleGlucuronidesLimit of DetectionLinear ModelsMaleMiceMice, Inbred C57BLRatsRats, Inbred F344Rats, Sprague-DawleyReproducibility of ResultsSulfatesTandem Mass SpectrometryFenoldopamGlucuronidesSulfatesFenoldopamFenoldopam-glucuronideFenoldopam-sulfateLC-MSPK

Identifiers

PMID34242859
PMCPMC8403159
OpenAlexW3179459258

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.